A new approach to treat ovarian cancer using combined antibodies
A Novel Symbiotic Approach for Ovarian Cancer
This study is testing a new treatment for late-stage ovarian cancer that combines two antibodies to help the immune system better attack cancer cells, with the hope of improving outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10621319 on NIH RePORTER |
What this research studies
This research investigates a novel treatment for late-stage ovarian cancer by developing a dual-specificity antibody that targets specific cancer markers. The approach aims to enhance the immune response against ovarian cancer cells by combining two previously ineffective antibodies into one. By utilizing the unique properties of ovarian cancer cells, the treatment seeks to improve the infiltration of immune cells into tumors, potentially leading to better outcomes for patients. The study will explore how this combined antibody can induce cell death in cancer cells more effectively than existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with late-stage ovarian cancer who have not responded to standard treatments.
Not a fit: Patients with early-stage ovarian cancer or those whose cancer is not associated with the targeted surface antigens may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for late-stage ovarian cancer, improving survival rates and quality of life for patients.
How similar studies have performed: While similar antibody-based approaches have shown promise in other cancers, this specific dual-target strategy is novel and has not been extensively tested in ovarian cancer.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Tushir-Singh, Jogender — University of California at Davis
- Study coordinator: Tushir-Singh, Jogender
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.